Zipalertinib
A tyrosine kinase inhibitor used in cancer treatment
| Zipalertinib | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Zipalertinib is a tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is designed to target specific mutations in cancer cells, thereby inhibiting their growth and proliferation.
Mechanism of Action[edit | edit source]
Zipalertinib functions by selectively inhibiting the activity of certain tyrosine kinases, which are enzymes involved in the signaling pathways that regulate cell division and survival. By blocking these enzymes, zipalertinib can prevent the growth of cancer cells that rely on these pathways for proliferation.
Clinical Development[edit | edit source]
Zipalertinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with different types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors. These trials aim to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of zipalertinib includes its absorption, distribution, metabolism, and excretion. Understanding these parameters is crucial for determining the appropriate dosing schedule and for predicting potential drug interactions.
Potential Side Effects[edit | edit source]
As with other tyrosine kinase inhibitors, zipalertinib may cause a range of side effects. Commonly reported adverse effects include fatigue, nausea, and diarrhea. More serious side effects may include cardiotoxicity and hepatotoxicity, which require careful monitoring during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from zipalertinib therapy. Additionally, studies are exploring the combination of zipalertinib with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
